563 related articles for article (PubMed ID: 30605011)
41. Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes.
Agarwal S; Sasane S; Kumar J; Deshmukh P; Bhayani H; Giri P; Giri S; Soman S; Kulkarni N; Jain M
Bioorg Med Chem Lett; 2018 Jun; 28(10):1849-1852. PubMed ID: 29655980
[TBL] [Abstract][Full Text] [Related]
42. Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5).
Chen T; Reich NW; Bell N; Finn PD; Rodriguez D; Kohler J; Kozuka K; He L; Spencer AG; Charmot D; Navre M; Carreras CW; Koo-McCoy S; Tabora J; Caldwell JS; Jacobs JW; Lewis JG
J Med Chem; 2018 Sep; 61(17):7589-7613. PubMed ID: 30141927
[TBL] [Abstract][Full Text] [Related]
43. TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.
Kaya D; Kaji K; Tsuji Y; Yamashita S; Kitagawa K; Ozutsumi T; Fujinaga Y; Takaya H; Kawaratani H; Moriya K; Namisaki T; Akahane T; Yoshiji H
Cells; 2019 Sep; 8(10):. PubMed ID: 31561561
[TBL] [Abstract][Full Text] [Related]
44. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
[TBL] [Abstract][Full Text] [Related]
45. Hepatic FOXA3 overexpression prevents Western diet-induced obesity and MASH through TGR5.
Gopoju R; Wang J; Pan X; Hu S; Lin L; Clark A; Xu Y; Yin L; Wang X; Zhang Y
J Lipid Res; 2024 Apr; 65(4):100527. PubMed ID: 38447926
[TBL] [Abstract][Full Text] [Related]
46. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets.
Higuera-de la Tijera F; Servín-Caamaño AI
World J Hepatol; 2015 Jun; 7(10):1297-301. PubMed ID: 26052375
[TBL] [Abstract][Full Text] [Related]
47. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
[TBL] [Abstract][Full Text] [Related]
48. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
49. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
[TBL] [Abstract][Full Text] [Related]
50. Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.
Cabrera D; Ruiz A; Cabello-Verrugio C; Brandan E; Estrada L; Pizarro M; Solis N; Torres J; Barrera F; Arrese M
Dig Dis Sci; 2016 Nov; 61(11):3190-3198. PubMed ID: 27572941
[TBL] [Abstract][Full Text] [Related]
51. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
52. Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism.
Gillard J; Picalausa C; Ullmer C; Adorini L; Staels B; Tailleux A; Leclercq IA
Nutrients; 2022 Jun; 14(13):. PubMed ID: 35807885
[TBL] [Abstract][Full Text] [Related]
53.
Wollman A; Daniel T; Rosenzweig T
Nutrients; 2019 Dec; 11(12):. PubMed ID: 31847157
[TBL] [Abstract][Full Text] [Related]
54. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide.
Long Z; Cao M; Su S; Wu G; Meng F; Wu H; Liu J; Yu W; Atabai K; Wang X
Free Radic Biol Med; 2017 Dec; 113():71-83. PubMed ID: 28942246
[TBL] [Abstract][Full Text] [Related]
56. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice.
Gan L; Meng ZJ; Xiong RB; Guo JQ; Lu XC; Zheng ZW; Deng YP; Luo BD; Zou F; Li H
Acta Pharmacol Sin; 2015 May; 36(5):597-605. PubMed ID: 25891086
[TBL] [Abstract][Full Text] [Related]
57. A rapid juvenile murine model of nonalcoholic steatohepatitis (NASH): Chronic intermittent hypoxia exacerbates Western diet-induced NASH.
Zhou J; Zhao Y; Guo YJ; Zhao YS; Liu H; Ren J; Li JR; Ji ES
Life Sci; 2021 Jul; 276():119403. PubMed ID: 33785339
[TBL] [Abstract][Full Text] [Related]
58. A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice.
Zheng C; Zhou W; Wang T; You P; Zhao Y; Yang Y; Wang X; Luo J; Chen Y; Liu M; Chen H
PLoS One; 2015; 10(7):e0134051. PubMed ID: 26208278
[TBL] [Abstract][Full Text] [Related]
59. Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
Kennedy L; Meadows V; Sybenga A; Demieville J; Chen L; Hargrove L; Ekser B; Dar W; Ceci L; Kundu D; Kyritsi K; Pham L; Zhou T; Glaser S; Meng F; Alpini G; Francis H
Hepatology; 2021 Jul; 74(1):164-182. PubMed ID: 33434322
[TBL] [Abstract][Full Text] [Related]
60. Red ginseng extracts ameliorate high-fat diet-induced obesity and insulin resistance by activating the intestinal TGR5-mediated bile acids signaling pathway.
Li W; Zhuang T; Wang Z; Wang X; Liu L; Luo Y; Wang R; Li L; Huang W; Wang Z; Yang L; Ding L
Phytomedicine; 2023 Oct; 119():154982. PubMed ID: 37531904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
